National Community Pharmacists Association | Strategic Alliance Partners

Senate, President Trump must also act soon to finally end spread pricing and reimbursement games in Medicaid, NCPA says

Government doles out billions to PBMs to stabilize premiums, but premiums keep rising along with PBM profits.

Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discussed concerns the association has with the implementation of the Medicare Drug Price Negotiation Plan.

New customizable letter also facilitates pharmacy outreach to area OB-GYNs.

Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discusses concerns about the implementation of the MDPNP.

A recent analysis from NCPA showed potential weekly cash flow shortfalls for pharmacies and annual revenue losses.

Arkansas HB 1150 a model for other states, federal government, organizations say.

Cases against PBMs and Big Insurers could be bogged by procedural hurdles if SCOTUS sides with petitioner, NCPA says.

Similar legislation could also address PBM practices in commercial insurance.

The Protecting Pharmacies in Medicaid Act aims to tackle spread pricing, but other legislation could target different issues.

Kaite Krell, MPH, discusses the critical role of independent pharmacies and how proposed legislation could address challenges with PBMs.

The legislation is expected to improve the financial stability of independent and community pharmacies by ensuring fair reimbursement rates and allowing them to better manage their finances.

Bill will protect pharmacies in Medicaid and save $2 billion over 10 years.

“Everyone agrees this must happen, so take the win and do it,” says CEO.

Remington Drug Company emphasizes importance of patient access to independent pharmacy care as FTC probe of PBMs continues.

Anticompetitive PBM tactics lead to higher costs, limited choices, and pharmacy deserts.

NCPA calls for immediate freeze of Medicare Drug Price Negotiation to protect pharmacies and patients.

Says the discount card company is colluding with the named PBMs to fix reimbursements

Investigation finds massive middlemen significantly hike patient costs for lifesaving drugs, skim billions for themselves, and reimburse their own pharmacies more than their competitors.

Congress fumbled a chance to rein in big insurance and PBMs and save taxpayers billions, says NCPA